KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been assigned a consensus rating of “Buy” from the eight analysts that are covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $24.83.

Several research analysts have issued reports on the company. Jones Trading restated a “buy” rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th.

Insider Activity

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average price of $9.42 per share, with a total value of $235,500.00. Following the completion of the purchase, the insider directly owned 5,303,985 shares of the company’s stock, valued at approximately $49,963,538.70. This represents a 0.47% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 2,776 shares of the business’s stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the transaction, the insider directly owned 106,611 shares of the company’s stock, valued at $1,262,274.24. This trade represents a 2.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,899 shares of company stock valued at $206,176. Corporate insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its stake in KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock worth $3,923,000 after buying an additional 12,263 shares in the last quarter. Rhumbline Advisers raised its stake in KalVista Pharmaceuticals by 3.4% in the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company’s stock worth $611,000 after buying an additional 1,762 shares in the last quarter. Woodline Partners LP grew its holdings in KalVista Pharmaceuticals by 25.5% in the first quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company’s stock worth $18,666,000 after purchasing an additional 329,068 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new position in KalVista Pharmaceuticals in the first quarter worth $8,698,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock worth $281,000 after purchasing an additional 2,939 shares during the last quarter.

KalVista Pharmaceuticals Trading Up 1.6%

KALV opened at $11.78 on Monday. The firm has a market cap of $585.70 million, a P/E ratio of -3.17 and a beta of -0.04. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $15.50. The stock has a 50-day moving average of $12.43 and a 200 day moving average of $10.95.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).